GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants

European Journal of Haematology

Volumn 84, Issue 4, 2010, Pages 323-331

  Olsson, Richard ^a   Remberger, Mats ^a   Hassan, Zuzana ^a   Omazic, Brigitta ^a   Mattsson, Jonas ^a   Ringdén, Olle ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cyclosporine A; Graft versus host disease prophylaxis; Haematopoietic stem cell transplantation; HLA identical sibling; Leukaemia

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVAL; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE FREE INTERVAL; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; INCIDENCE; LEUKEMIA REMISSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIBLING;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CYCLOSPORINE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; SIBLINGS; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 77949456123     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01390.x     Document Type: Article

References (31)

1. Storb R, Deeg HJ, Fisher L, et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 1988;71:293-8.
2. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989;73:1729-34.
3. Ringden O, Klaesson S, Sundberg B, Ljungman P, Lonnqvist B, Persson U. Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings. Bone Marrow Transplant 1992;9:19-25.
4. Ringden O, Horowitz MM, Sondel P, et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 1993;81:1094-101.
5. Ringden O, Backman L, Lonnqvist B, et al. A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies. Bone Marrow Transplant 1986;1:41-51.
6. Bacigalupo A, Van Lint MT, Occhini D, et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991;77:1423-8.
7. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981;304:1529-33.
8. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62.
9. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989;73:1720-8.
10. Yee GC, Self SG, McGuire TR, Carlin J, Sanders JE, Deeg HJ. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. N Engl J Med 1988;319:65-70.
11. Beelen DW, Quabeck K, Kaiser B, et al. Six weeks of continuous intravenous cyclosporine and short-course methotrexate as prophylaxis for acute graft-versus-host disease after allogeneic bone marrow transplantation. Transplantation 1990;50:421-7.
12. McGuire TR, Yee GC, Emerson S, Gmur DJ, Carlin J. Pharmacodynamic studies of cyclosporine in marrow transplant recipients. A comparison of three assay methods. Transplantation 1992;53:1272-5.
13. Kahan BD. Cyclosporine. N Engl J Med 1989;321:1725-38.
14. Storb R, Leisenring W, Anasetti C, et al. Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine? Biol Blood Marrow Transplant 1997;3:194-201.
15. Aschan J, Ringden O, Andstrom E, Ljungman P, Lonnqvist B, Remberger M. Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipients. Bone Marrow Transplant 1994;14:79-87.
16. Carlens S, Aschan J, Remberger M, Dilber S, Ringden O. Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia. Bone Marrow Transplant 1999;24:629-35.
17. Locatelli F, Zecca M, Rondelli R, et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood 2000;95:1572-9.
18. Ringden O, Remberger M, Persson U, et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995;15:619-25.
19. Gratwohl A, Stern M, Brand R, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a Retrospective Analysis. Cancer 2009;115:4715-26.
20. Ringden O, Ruutu T, Remberger M, et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994;83:2723-30.
21. Hentschke P, Hagglund H, Mattsson J, et al. Bilateral subdural haematomas following lumbar puncture in three haematopoietic stem cell transplant recipients. Bone Marrow Transplant 1999;24:1033-5.
22. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295-304.
23. Mohty M, Bilger K, Jourdan E, et al. Higher doses of CD34 + peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia 2003;17:869-75.
24. Carlens S, Ringden O, Remberger M, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 1998;22:755-61.
25. Carlens S, Ringden O, Aschan J, et al. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination. Clin Transplant 1998;12:84-92.
26. Mohty M, Kuentz M, Michallet M, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood 2002;100:3128-34.
27. Hagglund H, Bostrom L, Remberger M, Ljungman P, Nilsson B, Ringden O. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. Bone Marrow Transplant 1995;16:747-53.
28. Storb R, Prentice RL, Sullivan KM, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 1983;98:461-6.
29. Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990;75:2459-64.
30. Gratwohl A, Hermans J, Apperley J, et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood 1995;86:813-8.
31. Ringden O, Hermans J, Labopin M, Apperley J, Gorin NC, Gratwohl A. The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). Leuk Lymphoma 1996;2:71-9.